Sorrento Therapeutics (NASDAQ:SRNE) Research Coverage Started at StockNews.com

Analysts at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE) in a report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Sorrento Therapeutics Price Performance

NASDAQ SRNE opened at $0.02 on Monday. Sorrento Therapeutics has a 52-week low of $0.00 and a 52-week high of $0.42. The business’s 50-day moving average price is $0.02 and its 200 day moving average price is $0.05.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates.